Search Results - "Sujatta, M"

Ecarin Time Superior to Aptt in Monitoring Peghirudin Effects by Velagapudi, R., Badimon, J.J., Kyrle, P., Sujatta, M., Bodnar, J., Faulkner, R., Fettner, S., Hull, W., Cheesbro, J.

“…Clinical Pharmacology & Therapeutics (1999) 65, 194–194; doi:…”
Get full text

First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty by Schmid, K M, Preisack, M, Voelker, W, Sujatta, M, Karsch, K R

“…Restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) remains a major problem limiting the clinical efficacy of the procedure. It…”
Get more information

The induction of liver peroxisomal proliferation by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) by Hertz, R, Bar-Tana, J, Sujatta, M, Pill, J, Schmidt, F H, Fahimi, H D

“…Treatment of rats by beta,beta'-methyl-substituted hexadecanedioic acid (MEDICA 16) resulted in a dose- and time-dependent increase in liver peroxisomal…”
Get more information

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial) by Karsch, Karl R., Preisack, Melitta B., Baildon, Rainer, Eschenfelder, Volker, Foley, David, Garcia, Eulogio J., Kaltenbach, Martin, Meisner, Christoph, Selbmann, Hans K., Serruys, Patrick W., Shiu, Man F., Sujatta, Martin, Bonan, Raoul

“…Objectives. The specific objective of the REDUCE trial was to evaluate the effect of low molecular weight heparin on the incidence and occurrence of restenosis…”
Get full text

Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind Unfractionated Heparin and Placebo-Controlled Evaluation by Karsch, K R, Preisack, M B, Baildon, R, Eschenfelder, V, Foley, D, Garcia, E J, Kaltenbach, M, Meisner, C, Selbmann, H K, Serruys, P W, Shiu, M F, Sujatta, M, Bonan, R

“…The specific objective of the REDUCE trial was to evaluate the effect of low molecular weight heparin on the incidence and occurrence of restenosis in patients…”
Get full text

The short- and long-term effects of bezafibrate in the rat by Fahimi, H D, Reinicke, A, Sujatta, M, Yokota, S, Ozel, M, Hartig, F, Stegmeier, K

“…Bezafibrate is a potent hypolipidemic agent, which causes marked proliferation of peroxisomes in rat liver. At the same dosage, bezafibrate is more effective…”
Get more information

Report on the International Symposium on Low Molecular Weight Heparins and Related Polysaccharides. Munich, Germany, June 27 and 28, 1991 by Haas, P

Get more information

Low molecular weight heparin, reviparin, after PTCA: results of a randomized double-blind, standard heparin and placebo controlled multicenter study (REDUCE Study by Preisack, M B, Baildon, R, Eschenfelder, V, Foley, D, Garcia, E, Kaltenbach, M, Meisner, C, Selbmann, H K, Serruys, P W, Shiu, M F, Sujatta, M, Bonan, R, Karsch, K R

“…Unfractionated heparin and its low molecular fragments possess antiproliferative effects and have been shown to reduce neointimal smooth muscle cell migration…”
Get more information